Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Janux Therapeutics Inc (NQ: JANX )

48.82 -1.49 (-2.96%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Janux Therapeutics Inc

< Previous 1 2 3 Next >
Evaluating Janux Therapeutics: Insights From 6 Financial Analysts
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Cracking The Code: Understanding Analyst Reviews For Janux Therapeutics
Via Benzinga
Navigating 5 Analyst Ratings For Janux Therapeutics
Via Benzinga
Analyst Expectations For Janux Therapeutics's Future
Via Benzinga
JANX Stock Earnings: Janux Therapeutics Beats EPS, Beats Revenue for Q2 2024
JANX stock results show that Janux Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
The Latest Analyst Ratings For Janux Therapeutics
Via Benzinga
Analyst Ratings For Janux Therapeutics
Via Benzinga
A Glimpse Into The Expert Outlook On Janux Therapeutics Through 6 Analysts
Via Benzinga
Why Janux Therapeutics Stock Is Crushing It This Week
Janux's silence about a potential acquisition deal could be golden. 
Via The Motley Fool
GeneDx Leads Russell 2000 This Year As It Shifts To More Comprehensive Genetic Testing
GeneDx Holdings Corp. (NASDAQ: WGS) has soared 1,101% this year, attributed to its mix shift towards exome/genome testing and record high margins. 
Via Benzinga
UnitedHealth Posts Better-Than-Expected Earnings, Joins AngioDynamics, Bank of America And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
3 Biotech Stocks That Can Gain Exponentially By Leveraging AI
Although fraught with risk, these biotech exposures bring enormous upside potential. 
Via Talk Markets
Ambarella Posts Upbeat Results, Joins Gap, PagerDuty, Elastic And Other Big Stocks Moving Higher On Friday
Via Benzinga
Forecasting The Future: 4 Analyst Projections For Janux Therapeutics
Via Benzinga
JANX Stock Earnings: Janux Therapeutics Beats EPS, Beats Revenue for Q1 2024
JANX stock results show that Janux Therapeutics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
Take the Money and Run: 3 Overbought Stocks to Sell ASAP
Although speculators were smart enough to jump on these ideas, they’re currently overbought stocks that may require trimming. 
Via InvestorPlace
These 3 Biotech Stocks Are Up 269% in 2024. Is There More to Come?
These three biotech stocks are leading the sector higher on upbeat news but is this as good as it gets or do they have more gas in the tank? 
Via InvestorPlace
Why Fastenal Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Shares of Fastenal Company (NASDAQ: FAST) fell sharply during Thursday’s session following worse-than-expected first-quarter financial results. 
Via Benzinga
Why Is Cancer-Focused Janux Therapeutics Stock Trading Higher On Thursday?
Janux Therapeutics may be up for sale amid interest from major pharmaceutical firms. With shares quadrupling this year and a successful equity offering, Janux is making waves in the industry. The... 
Via Benzinga
Enliven Therapeutics, Alpine Immune Sciences, Janux Therapeutics And Other Big Stocks Moving Higher On Thursday
U.S. stocks were mixed, with the Dow Jones index falling over 50 points on Thursday. Shares of Enliven Therapeutics, Inc. (NASDAQ: ELVN) rose sharply during Thursday’s session. 
Via Benzinga
Topics Stocks
Exposures US Equities
Biotech Stocks Heat As Arvinas Scores Novartis Licensing Pact, Janux Reportedly Explores Options
Novartis snagged a licensing deal with Arvinas worth up to $1.16 billion, while Janux is said to be exploring its options. 
Via Investor's Business Daily
Why Janux Therapeutics Stock Soared as the Market Sagged Today
One of the hotter biotech companies on the scene might be changing owners before long. 
Via The Motley Fool
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Cancer-Focused Janux Therapeutics Platform Has 'Tremendous Opportunity': Analyst
Cantor Fitzgerald's coverage on Janux Therapeutics and its TRACTr/TRACir platform targeting diverse tumor antigens and cancer types. Analysts anticipate substantial growth potential driven by JANX007,... 
Via Benzinga
JANX Stock Earnings: Janux Therapeutics Beats EPS, Beats Revenue for Q4 2023
JANX stock results show that Janux Therapeutics beat analyst estimates for earnings per share and beat on revenue for the fourth quarter of 2023. 
Via InvestorPlace
2 Stocks That Have More Than Tripled This Year: Are They Buys?
Don't jump on the bandwaggon too quickly. 
Via The Motley Fool
B of A Securities Maintains Buy Rating for Janux Therapeutics: Here's What You Need To Know
Via Benzinga
5 Stocks That More Than Doubled In February
U.S. stocks rallied in February, with the S&P 500 and the Nasdaq Composite Index recording the best month in nearly a decade. Meanwhile, the Dow 
Via Talk Markets
Topics Stocks
Exposures US Equities
Why Asana Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Shares of Asana, Inc. (NYSE: ASAN) fell sharply during Tuesday’s session following soft FY25 revenue guidance. 
Via Benzinga
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS